Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more


Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with or ... Read more


Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more


Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with or ... Read more


Novo Nordisk A/S - Share repurchase programme ... Read more


Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

First phase 3a trial, PIONEER 1, with oral semaglutide successfully completed

22 February - Headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes were just published. CSO Mads Krogsgaard Thomsen said about the results: “We are very encouraged by the results of the PIONEER 1 trial, which confirm the unprecedented oral efficacy of semaglutide that was reported in the phase 2 clinical trial in type 2 diabetes. We look forward to providing data from the remaining nine PIONEER trials throughout this year and an expected regulatory submission in 2019.”

Read all the details about the trial in the announcement


Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes

9 February - "We are very excited about the approval of Ozempic® in the EU, as we believe it has the potential to set a new standard for the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer. "Type 2 diabetes is a complex disease and the strong clinical profile of Ozempic® provides a much needed treatment option for people looking for efficacious solutions to manage their disease."

Ozempic® was approved by the US FDA on 5 December 2017 and by Health Canada on 9 January 2018. 

Read the full announcement


Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)

1 February 2018 ­– Reported sales were broadly unchanged at DKK 112 billion (2% growth in local currencies)

Sales within diabetes care and obesity increased by 4% to DKK 92.9 billion (7% in local currencies).

  • Sales of Tresiba® increased by 81% to DKK 7.3 billion (85% in local currencies).
  • Sales of Victoza® increased by 16% to DKK 23.2 billion (18% in local currencies).
  • Sales of Saxenda® increased by 62% to DKK 2.6 billion (64% in local currencies) 

Lars Fruergaard Jørgensen, president and CEO: “I am pleased that we delivered on our plans for 2017 and we are continuing to build a platform for sustainable growth. The approval of Ozempic® in the USA was the culmination of a year in which we achieved important product approvals and label updates. In 2018, we will focus on the global launch of Ozempic® and pursue the full value potential of our strong product portfolio in what continues to be a competitive environment.”

Read all the details in the full announcement


Results from the SUSTAIN 7 trial published in The Lancet Diabetes & Endocrinology

1 February  ­– Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology

“It is imperative that clinical trial findings are published and made available to clinicians and the scientific community,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “SUSTAIN 7 is an important head-to-head trial, demonstrating significant efficacy of once-weekly semaglutide vs dulaglutide, and we are pleased that the full manuscript is now available in The Lancet Diabetes & Endocrinology.”

Read the full press release


Mads Krogsgaard Thomsen, CSO, photographer Esben Salling

The pursuit of oral insulin

10 November - It’s been 12 months since Novo Nordisk made the difficult decision to discontinue its oral insulin development programme. Chief Science Officer Mads Krogsgaard Thomsen reflects on a year of learning, on what motivates him and his team and on the possibility to one day revisit the potential of oral insulin.

Read the whole story of the pursuit oral insulin


Houston, Texas

Cities Changing Diabetes summit in Houston, TX

26 October - Cases of diabetes are accelerating in every part of the world meaning that today, one  in 11 adults live with the condition.1 The report – Bending the Curve on Urban Diabetes – urges governments, city and health leaders to make changing the trajectory of the disease a top global priority in order to ‘bend the rising curve’ of diabetes prevalence.

An international coalition of cities is calling for an ambitious global goal to prevent more than 100 million new cases of diabetes by 2045; new research published in a report by the Cities Changing Diabetes partnership is launched today at a global summit in Houston, Texas. The report comes with the stark warning that achieving the goal requires cutting rates of obesity by a quarter. 

Download the release

Read more about Cities Changing Diabetes


New beginnings

With millions displaced by war, business has a key role in helping refugees integrate, contribute and flourish in society. Each individual you meet has their own personal backstory of despair and upheaval. Days on end spent on an over-crowded boat, bobbing on the Mediterranean. Families fragmented and dispersed. Careers and livelihoods abruptly curtailed.

Read the story about refugees in our programmes

Novo Nordisk refugee programmes

The hidden talents

Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.

Read the whole story

Louise Wille

Sarah Ahmed from Ethopia has type 1 diabetes

Novo Nordisk committed to guarantee access to insulin

Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.

Read all the details about Novo Nordisk's programme on access to insulin

The diabetes challenge - get an overview of Novo Nordisk's commitment 


Q1 financial results

Annual report 2017

Get an instant impression of what Novo Nordisk is about, see the numbers and read the articles, eg 'It takes more than medicine to defeat diabetes

Healthy growth

Contribution to a national life science strategy in Denmark from Novo Nordisk, Lundbeck and LEO Pharma.

Download the pdf 
(Danish only)!

Novo Nordisk in brief